Price Summary

FinStar

Ownership Stable

Ownership strength is slightly missing the benchmark.

ValuationAttractive

The stock is considerably attractive based on intrinsic value.

EfficiencyPoor

The company seems highly inefficient in case of asset management.

FinancialsVery Stable

The company possesses stable growth history and manageable debt.

Company Essentials

Enterprise Value

2915.1 Cr.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

RelonChem Time-Caps labs Bells Healthcare NOVA

 Group Companies

Ratios

Sales Growth

1 Year2.18%

3 Year26.16%

5 Year1.34%

Profit Growth

1 Year-13.1%

3 Year48.63%

5 Year-10.8%

ROE%

1 Year7.77%

3 Year6.8%

5 Year8.42%

ROCE %

1 Year11.39%

3 Year9.43%

5 Year10.84%

Interest Cover Ratio

8.23106411875313

CFO/PAT (5 Yr. Avg.)

1.15600858787058

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 48.25 0
Mar 2021 48.25 0
Dec 2020 48.25 0
Sep 2020 48.25 0
Jun 2020 48.25 0

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 155.96 137.55 168.46 137.58 147.22
Total Expenditure 126.96 114.5 133.57 110.8 122.12
Operating Profit 29 23.05 34.88 26.78 25.1
Other Income 0.05 12.96 6.24 11.91 13.94
Interest 0.79 1.32 1.1 2.14 0.63
Depreciation 3.34 3.67 4.03 4.15 4.23
Exceptional Items 0 0 0 0 0
Profit Before Tax 24.92 31.01 35.99 32.4 34.18
Tax 2.87 7.48 6.89 8.72 5.27
Profit After Tax 22.06 23.54 29.1 23.69 28.91
Adjusted EPS (Rs) 0.54 0.58 0.71 0.58 0.71

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 358.13 215.84 294.66 424.16 433.42
Total Expenditure 258.76 202.15 265.52 360.83 361.93
Operating Profit 99.38 13.69 29.15 63.33 71.49
Other Income 13.21 17.75 7.43 7.93 0.17
Interest 6.2 4.49 7.67 6.56 7.29
Depreciation 14.75 15 12.25 8.69 11.64
Exceptional Items 0 0 0 0 0
Profit Before Tax 91.63 11.95 16.65 56.01 52.73
Tax 20.14 0.4 4.23 12.39 14.82
Net Profit 71.49 11.55 12.43 43.62 37.9
Adjusted EPS (Rs.) 1.75 0.28 0.3 1.07 0.93

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 53.43 40.93 40.93 40.93 40.93
Total Reserves 369.27 377.95 388.04 429.64 464.69
Borrowings 0 0 0 0 0
Other N/C liabilities 0.31 17.3 17.09 18.39 28.03
Current liabilities 111.19 109.59 111.22 133.39 71.9
Total Liabilities 534.2 545.77 557.29 622.35 605.55
Assets
Net Block 97.47 93.92 87.89 102.61 115.18
Capital WIP 0 0.36 0 0 0
Intangible WIP 0 0 0 0 0
Investments 231.44 234.29 236.07 236.07 236.07
Loans & Advances 1.25 0.59 0.82 1.29 2.05
Other N/C Assets 0 0 0 0 0
Current Assets 204.04 216.61 232.51 282.37 252.25
Total Assets 534.2 545.77 557.29 622.35 605.55

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit from operations 91.63 11.95 16.65 56.01 52.73
Adjustment 8.82 12.5 20 11.57 19.17
Changes in Assets & Liabilities -15.35 -22.39 -16.33 -34.91 56.6
Tax Paid -20.33 -15.69 -4.68 -12.86 -10.49
Operating Cash Flow 64.76 -13.62 15.63 19.81 118.01
Investing Cash Flow -177.34 -7.69 -7.55 -20.2 -24.1
Financing Cash Flow -51.83 20.74 -9.98 0.96 -92.29
Net Cash Flow -164.41 -0.57 -1.9 0.56 1.63

Corporate Actions

Super Investors

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 47.8 46.76 46.4 47.07 48.05
mukul mahavir prasad agra... 1.95 1.95 1.95 1.95 1.47
ashish kacholia 0 1.25 1.25 1.25 0
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 3.95 4.99 5.35 4.68 3.7

Marksans Pharma Stock Price Analysis and Quick Research Report. Is Marksans Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Marksans Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 118.0141634 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Marksans Pharma has a Debt to Equity ratio of 0.0001 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Marksans Pharma , the EPS growth was -13.1006006006006 % which is bad for the company.
     
  • Operating profit margin: It determines a companys potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Marksans Pharma has OPM of 16.4944921825364 % which is a good sign for profitability.
     
  • ROE: Marksans Pharma have a poor ROE of 7.76549882596146 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholders fund is used for generating profits.
Brief about Marksans Pharma

Tell us about you

Find us at the office

Kajioka- Constanza street no. 39, 50889 Kuala Lumpur, Malaysia

Give us a ring

Deunte Staunton
+59 850 269 756
Mon - Fri, 10:00-14:00

Reach out